Sclerodermatous eruption in a patient with metastatic colon cancer treated with an FLT3/CDK inhibitor

Australas J Dermatol. 2023 Aug;64(3):e272-e274. doi: 10.1111/ajd.14093. Epub 2023 May 31.

Authors

Henry Zou¹, Hany Deirawan², Dipesh Uprety², Steven Daveluy²

Affiliations

¹ Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.
² Wayne State University School of Medicine, Detroit, Michigan, USA.

PMID: 37255338
DOI: 10.1111/ajd.14093

No abstract available

Keywords: FLT3/CDK inhibitor; FN-1501; metastatic colon adenocarcinoma; scleroderma; systemic sclerosis (SSc); tyrosine kinase.

MeSH terms

Colonic Neoplasms* / drug therapy
Exanthema*
Humans
Protein Kinase Inhibitors / adverse effects
Scleroderma, Localized*
fms-Like Tyrosine Kinase 3

Substances

Protein Kinase Inhibitors
FLT3 protein, human
fms-Like Tyrosine Kinase 3